Pure Global AI
NCT06419140Not yet recruiting

Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy

The Impact of Multimodal Rehabilitation on the Outcomes of Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy: A Phase II, Multicenter, Open Label, and Randomized Clinical Study
Zhejiang Cancer HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Zhejiang Cancer Hospital
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Dec 31, 2025
Enrollment
138 participants
Primary outcome

Adjuvant chemotherapy completion rate

Summary

This study has established a multidisciplinary rehabilitation team to recruit patients who
 underwent radical D2 gastrectomy in multiple centers and divided them into a rehabilitation
 group and a control group. Intervention will be carried out every time the patients come to
 the hospital for adjuvant chemotherapy and review. The control group uses traditional
 intervention model, and the rehabilitation group uses combined exercise/nutrition/psychology
 rehabilitation intervention.
 
 This study is expected to promote early recovery after gastric cancer surgery through
 multidisciplinary rehabilitation intervention, reduce the occurrence of complications,
 improve patients' tolerance to adjuvant chemotherapy, and improve patients' quality of life,
 and hope to improve the short-term and long-term outcomes of gastric cancer patients.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419140
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419140 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 138 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.